ReproCELL Incorporated【JP:4978】Stock Price

Reprocell operates businesses utilizing iPS cell technology, divided primarily into two segments: "Research Support Business" and "Medical Business." The Research Support Business provides research products using iPS cells and contract services to universities and pharmaceutical companies, establishing a revenue base for the near to medium term.

In the Research Support Business, Reprocell sells research reagents such as culture media and antibodies necessary for iPS cell research. In particular, "Primate ES Cell Medium" is known as the product used when human iPS cell creation was first successfully achieved. Additionally, REPROCELL USA provides human biological samples including cancer cells and blood, supporting pharmaceutical company research.

The Medical Business handles research and development of regenerative medicine products, contract manufacturing, and clinical testing services. Reprocell is advancing development of regenerative medicine products such as StemCymate and iPS neural glial cell products, which are positioned as pillars of medium to long-term growth. The company also conducts research and development of advanced therapies including TIL therapy and GPC-1 CAR-T therapy.

Reprocell manufactures highly safe iPS cells using RNA reprogramming technology and supplies them to pharmaceutical companies. For individual consumers, the company operates a "Personal iPS" service that creates and stores iPS cells in preparation for future disease treatment. This is expected to reduce treatment duration and lower the risk of immune rejection.

In clinical testing contract services, Reprocell provides testing such as HLA typing and conducts business with medical institutions nationwide. The company also operates "Wellmil," a mail-in testing service that allows individuals to check their health status at home, offering stress and hormone balance testing. This supports personal health management.

Reprocell has established a growth strategy based on iPS cell technology. In the short to medium term, the company is strengthening its "Research Support Business," providing research products and services using iPS cells. This builds a revenue foundation targeting universities and pharmaceutical companies.

In the medium to long term, Reprocell is focusing on its "Medical Business," advancing the development of regenerative medicine products. The company is conducting research and development on Stemchymal and iPS neural glia cell products, aiming for early regulatory approval for manufacturing and sales. Through this, Reprocell seeks to establish leadership in the regenerative medicine market.

Reprocell is actively pursuing global expansion. The company maintains operations in Japan, the United States, Europe, and India, conducting sales, manufacturing, and research and development in each region. This enables access to universities and pharmaceutical companies worldwide, driving revenue growth.

Additionally, Reprocell prioritizes technological innovation, securing competitive advantage by adopting cutting-edge technology. Through partnerships with universities and companies domestically and internationally, the company is developing new business opportunities and pursuing sustainable growth.